More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

With no differences between single or dual antiplatelet therapy or anticoagulants at 6 months, an RCT is warranted for ...

Common antiplatelet medications include aspirin, which inhibits the enzyme cyclooxygenase-1 (COX-1), and clopidogrel, which blocks the P2Y12 receptor on platelets. By preventing platelets from ...

The following is a summary of “Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: ...

Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its superior antiplatelet potency compared with ...

Singh, A. , Sinha, R. , Saran, M. , Kazmi, D. , Gupta, H. and Seth, G. (2025) Efficacy and Safety of Dual Antiplatelet Therapy in High-Risk, Post-Percutaneous Coronary Intervention Patients beyond One ...

The 2025 guideline introduces notable updates including refined recommendations for dual antiplatelet therapy, cardiogenic ...

De-escalating dual antiplatelet therapy from from aspirin plus ticagrelor to aspirin plus clopidogrel after primary ...

The American College of Cardiology and American Heart Association issued updated practice guidelines for the management of patients with acute coronary syndrome.The document was developed in ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower ...